SK bioscience

Since entering the vaccine industry in 2001, SK bioscience has established world-class R&D and manufacturing capabilities. The company commercialized SKYCellflu®, a cell culture-based influenza vaccine, SKYZoster® for shingles, and SKYVaricella® for chickenpox, with SKYCellflu® and SKYVaricella® achieving WHO Prequalification.

Its manufacturing facility, L House in Andong, operational since 2012, features flexible multi-modular and single-use systems capable of producing a wide range of vaccines.

Since 2020, SK bioscience has accelerated its global expansion through the development and commercialization of Korea’s first homegrown COVID-19 vaccine, SKYCovione™, as well as global CMO/CDMO partnerships.

Currently, SK bioscience is expanding its portfolio into next-generation infectious disease prevention platforms. Key projects include GBP410, a 21-valent pneumococcal conjugate vaccine being developed with Sanofi; GBP511, a pan-sarbecovirus vaccine candidate; and RSM01, an RSV preventive monoclonal antibody for infants.

In 2024, SK bioscience acquired a controlling stake in Germany-based IDT Biologika, establishing a manufacturing base in Europe and significantly expanding its global CDMO capabilities.

In 2026, SK bioscience opened ECO Bio, its new headquarters and integrated R&D center in Songdo. With this new hub, the company continues to expand its global footprint through R&D innovation, manufacturing excellence, and strategic partnerships to deliver solutions for infectious disease prevention worldwide.